X

Trial Profile

A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Onilcamotide (Primary) ; Montanide ISA-51
Indications Adenocarcinoma; Prostate cancer
Focus Proof of concept; Therapeutic Use
Acronyms BRaVac
Sponsors CHOSA Oncology

Most Recent Events

10 Feb 2023 According to a CHOSA Oncology media release, RhoVac AB changes name to CHOSA Oncology AB.
22 Aug 2022 This trial has completed in Denmark, as per European Clinical Trials Database record.
14 Aug 2022 This trial has been completed in Sweden (End Date: 2 June 2022) as per European Clinical Trials Database record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com